Display options
Cite
Kolkhof P, Hartmann E, Freyberger A, et al. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-652doi: 10.1159/000516213.
Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021). Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. American journal of nephrology, 52(8), 642-652. https://doi.org/10.1159/000516213
Kolkhof, Peter, et al. "Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage." American journal of nephrology vol. 52,8 (2021): 642-652. doi: https://doi.org/10.1159/000516213
Kolkhof P, Hartmann E, Freyberger A, Pavkovic M, Mathar I, Sandner P, Droebner K, Joseph A, Hüser J, Eitner F. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage. Am J Nephrol. 2021;52(8):642-652. doi: 10.1159/000516213. Epub 2021 Jun 10. PMID: 34111864; PMCID: PMC8619789.
Copy Download .nbib Format: NLM
Share it on

Am J Nephrol. 2021;52(8):642-652. doi: 10.1159/000516213. Epub 2021 Jun 10.

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.

American journal of nephrology

Peter Kolkhof, Elke Hartmann, Alexius Freyberger, Mira Pavkovic, Ilka Mathar, Peter Sandner, Karoline Droebner, Amer Joseph, Jörg Hüser, Frank Eitner

Affiliations

  1. Cardiovascular Research, Research and Early Development, R&D Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  2. Research Pathology, Research and Early Development, R&D Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  3. Clinical Pathology, Research and Early Development, R&D Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  4. Biomarker Research, Research and Early Development, R&D Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  5. Clinical Development, R&D Pharmaceuticals, Bayer AG, Berlin, Germany.

PMID: 34111864 PMCID: PMC8619789 DOI: 10.1159/000516213

Abstract

INTRODUCTION: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated clinical benefits in CKD patients with type 2 diabetes. Clinical data analyzing the potential value of a combination therapy are currently limited. We therefore investigated cardiorenal protection of respective mono- and combination therapy in a preclinical model of hypertension-induced end-organ damage.

METHODS: Cardiovascular (CV) morbidity and mortality were studied in hypertensive, N(ω)-nitro-L-arginine methyl ester-treated, renin-transgenic (mRen2)27 rats. Rats (10- to 11-week-old females, n = 13-17/group) were treated once daily orally for up to 7 weeks with placebo, finerenone (1 and 3 mg/kg), empagliflozin (3 and 10 mg/kg), or a combination of the respective low doses. Key outcome parameters included mortality, proteinuria, plasma creatinine and uric acid, blood pressure, and cardiac and renal histology.

RESULTS: Placebo-treated rats demonstrated a 50% survival rate over the course of 7 weeks. Drug treatment resulted in variable degrees of survival benefit, most prominently in the low-dose combination group with a survival benefit of 93%. Monotherapies of finerenone or empagliflozin dose-dependently reduced proteinuria, while low-dose combination revealed an early, sustained, and over-additive reduction in proteinuria. Empagliflozin induced a strong and dose-dependent increase in urinary glucose excretion which was not influenced by finerenone coadministration in the combination arm. Low-dose combination but not respective low-dose monotherapies significantly reduced plasma creatinine and plasma uric acid after 6 weeks. Treatment with finerenone and the low-dose combination significantly decreased systolic blood pressure after 5 weeks. There was a dose-dependent protection from cardiac and kidney fibrosis and vasculopathy with both agents, while low-dose combination therapy was more efficient than the respective monotherapy dosages on most cardiorenal histology parameters.

DISCUSSION/CONCLUSIONS: Nonsteroidal MR antagonism by finerenone and SGLT2 inhibition by empagliflozin confer CV protection in preclinical hypertension-induced cardiorenal disease. Combination of these 2 independent modes of action at low dosages revealed efficacious reduction in important functional parameters such as proteinuria and blood pressure, plasma markers including creatinine and uric acid, cardiac and renal lesions as determined by histopathology, and mortality indicating a strong potential for combined clinical use in cardiorenal patient populations.

The Author(s). Published by S. Karger AG, Basel.

Keywords: Anti-fibrotic effects; Cardiorenal protection; Mineralocorticoid receptor antagonism; Sodium-glucose cotransporter-2 inhibition

References

  1. JAMA. 2015 Sep 1;314(9):884-94 - PubMed
  2. N Engl J Med. 2016 Mar 17;374(11):1094 - PubMed
  3. Acta Physiol (Oxf). 2021 Jul;232(3):e13589 - PubMed
  4. N Engl J Med. 2020 Oct 8;383(15):1413-1424 - PubMed
  5. Hypertension. 2005 Dec;46(6):1227-35 - PubMed
  6. Nature. 1990 Apr 5;344(6266):541-4 - PubMed
  7. Kidney Int. 2011 May;79(10):1051-60 - PubMed
  8. Diabetologia. 2018 Oct;61(10):2134-2139 - PubMed
  9. Trends Endocrinol Metab. 2015 Apr;26(4):201-11 - PubMed
  10. N Engl J Med. 2019 Jun 13;380(24):2295-2306 - PubMed
  11. Regul Pept. 1998 Oct 16;77(1-3):3-8 - PubMed
  12. N Engl J Med. 2020 Dec 03;383(23):2219-2229 - PubMed
  13. Hypertension. 2012 Feb;59(2):500-6 - PubMed
  14. Handb Exp Pharmacol. 2017;243:271-305 - PubMed
  15. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:16-31 - PubMed
  16. Dis Model Mech. 2016 Dec 1;9(12):1419-1433 - PubMed
  17. N Engl J Med. 2016 Jul 28;375(4):323-34 - PubMed
  18. N Engl J Med. 2020 Oct 8;383(15):1436-1446 - PubMed
  19. Eur Heart J. 2016 Jul 14;37(27):2129-2200 - PubMed
  20. Kidney Int. 1992 Jan;41(1):24-36 - PubMed
  21. J Pharmacol Exp Ther. 2014 Sep;350(3):657-64 - PubMed
  22. Circulation. 2021 Feb 9;143(6):540-552 - PubMed
  23. Am J Hypertens. 1997 Feb;10(2):209-16 - PubMed
  24. Kidney Int. 2019 Aug;96(2):302-319 - PubMed
  25. JACC Heart Fail. 2018 Aug;6(8):633-639 - PubMed
  26. ChemMedChem. 2012 Aug;7(8):1385-403 - PubMed
  27. J Cardiovasc Pharmacol. 2014 Jul;64(1):69-78 - PubMed
  28. Eur Heart J. 2021 Jan 7;42(2):152-161 - PubMed
  29. Annu Rev Med. 2015;66:255-70 - PubMed
  30. J Am Heart Assoc. 2019 Apr 2;8(7):e011426 - PubMed
  31. Pharmacol Rev. 2016 Jan;68(1):49-75 - PubMed

Publication Types